Now, children between 2 and 18 years of age will also get corona vaccine, Modi govt approves vaccine

New Delhi: A big news has emerged about the Corona vaccine vaccine manufactured by Bharat Biotech. Now children between the ages of 2 and 18 can be given covaxin supplements. It has been approved by the DGCI. Tell us that Bharat Biotech and ICMR have developed covaxin together. It is a completely Indian corona vaccine. Significantly, Covaxin taqriban was 78 percent effective in clinical trials against the corona virus.

Tell us that new cases of corona are continuously declining in the country. In the last 24 hours, 14, 313 new corona cases have been reported, the lowest ever in the last 224 days. The current recovery rate was recorded at 98.04 per cent, the highest since March 2020. With 26,579 healthy in the last 24 hours, the total recovery rate has increased to 3,33,20,057. So far, 95.89 crore people in the country have been given corona vaccine supplements.

According to the same reported reports, active cases are less than 1% of the total cases, which is currently 0.63%. These are the lowest cases since March 2020. India's active caesloed is 2,14,900, the lowest in 212 days. The weekly positivity rate (1.48%) for the last 109 days is less than 3%. The daily positivity rate (1.21%) is less than 3% for the last 43 days. As of October 11, 2021, 58,50,38,043 samples of corona were tested in the country. Out of these, 11,81,766 samples were tested yesterday. This was reported by the Indian Council of Medical Research.

Bangladeshis enter India via Bengal by paying Rs. 5,000, then commit dacoity... Big Gang Busted

Follow protocol for MPs, Civil Aviation Ministry tells all airlines

Bollywood actress supports Shah Rukh Khan by sharing poetry

Disclaimer : The views, opinions, positions or strategies expressed by the authors and those providing comments are theirs alone, and do not necessarily reflect the views, opinions, positions or strategies of NTIPL, english.newstracklive.com or any employee thereof. NTIPL makes no representations as to accuracy, completeness, correctness, suitability, or validity of any information on this site and will not be liable for any errors, omissions, or delays in this information or any losses, injuries, or damages arising from its display or use.
NTIPL reserves the right to delete, edit, or alter in any manner it sees fit comments that it, in its sole discretion, deems to be obscene, offensive, defamatory, threatening, in violation of trademark, copyright or other laws, or is otherwise unacceptable.
- Sponsored Advert -

Most Popular

- Sponsored Advert -